Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk
Clin J Am Soc Nephrol. 2024 Oct 8.
doi: 10.2215/CJN.0000000587.
Online ahead of print.
1 Department of Pharmacotherapy, Washington State University, Spokane, Washington.
2 Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut.
3 Division of Health Care Delivery Research, Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, Minnesota.
4 OptumLabs, Eden Prairie, Minnesota.
5 Department of Public Health Sciences, University of Chicago, Chicago, Illinois.
6 Division of Endocrinology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida.
7 Division of Endocrinology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
8 Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
9 Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut.
10 Division of Endocrinology, Diabetes, and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
11 University of Maryland Institute for Health Computing, North Bethesda, Maryland.